CureMatch
×
  • Physicians
    • Patients
  • About Us
  • News
    • CureMatch News
    • Validation and Research
    • Events & Conferences
  • Contact

CureMatch Provides Optimism to Pancreatic Cancer Patients

CureMatch Provides Optimism to Pancreatic Cancer Patients
Blog Posts

“You have pancreatic cancer” – Shock, sadness, worry, and fear are all emotions that cancer patients may feel when hearing such devastating prognosis. To make matters worse, pancreatic cancer is expected to become the second leading cause of cancer deaths in the US by 2020 and stage IV pancreatic cancer patients have an average survival rate of only 1.5% after 5 years.1, 2 Pancreatic cancer is also difficult to detect because there are no signs or symptoms in early stages of the cancer. Additionally, early symptoms often share similarities with other types of illnesses resulting in either a wrong diagnosis or catching the cancer at an advanced stage.

Currently, most healthcare providers may suggest one or a combination of the following treatments:

Common Treatments for Pancreatic Cancer

Prescribed Treatment ~% Patients Receiving TreatmentTreatment Description
Whipple Procedure 

20%

Surgery which removes the head of the pancreas next to the small intestine or duodenum
External Beam TherapyHigh energy x-ray radiation
Chemotherapy Drugs Alone or Combined with Erlotinib80%Usually gemcitabine, capecitabine, FOLFOX, or gemcitabine + erlotinib

 

Although the Whipple procedure and external beam therapy are effective in treating pancreatic cancer, they can only be administered if the cancer is diagnosed early. Because current diagnostic tools have failed to provide early detection in many cases, only 20% of patients are able to receive either surgery or external beam therapy. Thus, most patients must rely on pharmaceutical treatments.2, 3

Inspection of clinical trials treating pancreatic cancer show that over 72% of them use chemotherapy drugs. From the chemotherapy drugs administered, the majority use gemcitabine and report a short 4-month progression-free survival value (the amount of time until the disease begins to progress in patients). Only 28% of clinical trials employ a more targeted strategy which consists primarily of combining gemcitabine with erlotinib (a drug specific to inhibiting the epidermal growth factor receptor or EGFR). Yet, combining gemcitabine with erlotinib yields a similar progression-free survival value as gemcitabine alone.

These results raise several concerning questions:

  • Why are the same treatments being given despite a clear lack of success?
  • Why does the more targeted method of using erlotinib combined with gemcitabine not work?

Unfortunately, especially with pancreatic cancer, all of this appears to be indicative of resignation on part of the healthcare industry. For one, the targeted strategy of combining gemcitabine with erlotinib is ineffective because it ignores the uniqueness of each patient’s tumor, and while the treatment may work for some patients, it will not work for everyone. Additionally, EGFR mutations are not very prevalent in pancreatic cancer (~7% of patients carry an EGFR mutation) making erlotinib an ineffective treatment. Second, few healthcare providers are willing to break the status quo and try different treatments. However, the last thing pancreatic cancer patients want to hear is that there is no hope and are instead given a treatment that we know won’t and hasn’t worked in the past decade.

Luckily, there is a fourth option: CureMatch

curematch-report-screenshot

As a trailblazer of precision medicine, CureMatch offers oncologists a report that can guide selection of personalized therapies, including targeted therapy, immunotherapy, hormone therapy, and the latest cancer drugs, either alone or in combination.

By analyzing more than 4.5 million different drug regimens and ranking the most advanced cancer treatments using supercomputing technology, the best drug regimen is selected based on the genetic profile of the individual.

As exemplified in one study, based on the genetic profile of a patient with pancreatic cancer, trametinib (a drug specific to inhibiting the mitogen-activated protein kinase pathway) was predicted by the CureMatch scoring system to have one of the best outcomes for that patient. As projected, this patient had a Time to Failure of 10 months (time of treatment to disease progression) which is an exceptional response.4

Even if some drugs are not covered by insurance companies for some diseases, the CureMatch software considers the latest research on biomarkers (which are gene mutations present in cancer patients that are known to increase the drug’s efficacy) for available drugs. Doing so, CureMatch analyzes FDA approved drugs most appropriate for each patient.

Still, CureMatch is much more than just curated databases and complex algorithms, it is a company composed of scientific individuals who are constantly on the lookout for the latest cancer discoveries. For example, it has been revealed that one of the boundaries to treating pancreatic cancer is partly attributed to the pancreas stroma as shown below:

pancreatic cancer stroma

Fig 1: The left image show tissues of a normal pancreas, while the image on the right shows cancerous pancreatic tissue. The main difference is the fibrotic and poorly diffused stroma that is evident in the right image.

Due to the dense and fibrotic stroma, it is difficult for drugs to reach its target site and effectively kill cancer cells. To circumvent this impasse, new nanoparticle drugs (which can penetrate the stroma) or hedgehog inhibitor drugs (shown to damage the stroma) may be part of the solution in treating this disease. The CureMatch decision platform takes these scientific discoveries into account and may suggest a drug combination that also contains a hedgehog inhibitor and/or a nanoparticle drug.

Ultimately, your healthcare provider is likely to be resigned to the same ineffective one-size-fits-all approach; this is not only devastating to the patient, but is also unfortunate for the pancreatic cancer research community in general, which has found many more promising solutions.

Hope For Pancreatic Cancer Patients

CureMatch can guide the oncologist to take an innovative approach that considers all possible treatment options and personalizes them specifically for each individual patient.

-Alexander Schperberg

  1. Key Statistics for Pancreatic Cancer. Available at: https://www.cancer.org/cancer/pancreatic-cancer/about/key-statistics.html. [Accessed: 7th April 2017]
  2. Mosquera, C., Maglic, D. & Zervos, E. E. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials. Cancer Genet. 209, 567–581 (2016).
  3. National Cancer Institute. (2017). Pancreatic Cancer Treatment. [online] Available at: https://www.cancer.gov/types/pancreatic/patient/pancreatic-treatment-pdq [Accessed 4 Aug. 2017].
  4. Garrido-Laguna I, Tometich D, Hu N, Ying J, Geiersbach K, Whisenant J, et al. N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012. Oncoscience. 2015;2(3):285‑93.

Figure 1 image provided by:

Institute of Molecular Biology and Tumor Research: Imt.uni-marburg.de. (2017). IMT Marburg – AG Lauth – Research. [online] Available at: http://www.imt.uni-marburg.de/lauth/research.php [Accessed 4 Aug. 2017].

Share

  • LinkedIn
  • Facebook
  • Twitter
  • Reddit
  • Email
  • Print

Receive CureMatch News

Sign up for personalized oncology information and resources.
* = required field

Recent News & Resources

  • CureMatch Appoints Visionary Leader, Ally Perlina, as Chief Science Officer

    Leader brings two decades of industry experience in precision medicine, pharmaceutical and translational science to...

  • Biomarkers Aren’t Consistently Used to Select Participants for Immunotherapy Trials

    Only a minority of clinical trials evaluating immunotherapeutic agents in 2019 used a biomarker to...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for patients with cancer....

  • Servier and CureMatch® Launch Their Self-Certified CE-Marked Clinical Decision Support Software, Bionov™

    PARIS and SAN DIEGO, Oct. 12, 2020 /PRNewswire/ — WeHealth™ Digital Medicine, Servier Group’s e-health business unit, and CureMatch®, a...

  • How Precision Medicine Can Help You

    Precision medicine is revolutionizing cancer care. Dr. Razelle Kurzrock highlights how personalized treatments improve patient...

  • 64 FDA-Approved Drugs Identified as Potential Treatments for COVID-19

    Scientists from CureMatch and UCSD use pharmacophore-based drug design and a molecular docking technique to...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription drugs in the...

Validation

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription...

  • CureMatch at WIN Symposium 2018 Winning the War against Cancer with Precision Oncology

    SAN DIEGO, CA – June 22, 2018 – CureMatch, Inc. offers results...

  • Personalized Drug Combinations Can Lead to Better Results for Cancer Patients

    A featured article in The Scientist magazine highlights CureMatch co-founder Dr. Razelle...

Archives

  • December 2020 (2)
  • October 2020 (3)
  • April 2020 (1)
  • November 2019 (2)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (2)
  • March 2019 (2)
  • September 2018 (1)
  • August 2018 (1)
  • July 2018 (1)
  • June 2018 (5)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (3)
  • January 2018 (4)
  • December 2017 (3)
  • November 2017 (1)
  • October 2017 (1)
  • September 2017 (3)
  • August 2017 (4)
  • June 2017 (6)
  • May 2017 (9)
  • April 2017 (11)
  • March 2017 (8)
  • February 2017 (3)
  • January 2017 (5)
  • October 2016 (1)
  • September 2016 (5)
  • August 2016 (2)
  • May 2016 (1)
  • April 2016 (1)

logo

+1 (858) 859-2873

FAX: +1 (858) 430-5813

Quick Links

  • Physicians
  • About CureMatch
  • News and Latest Posts
    • CureMatch News
    • Validation and Case Studies
    • Events and Conferences
  • Contact Us
  • FAQ

Latest News and Results

  • CureMatch Appoints Visionary Leader, Ally Perlina, as Chief Science Officer Dec 15

    Leader brings two decades of industry experience in precision medicine, pharmaceutical and translational science to...

  • Biomarkers Aren’t Consistently Used to Select Participants for Immunotherapy Trials Dec 13

    Only a minority of clinical trials evaluating immunotherapeutic agents in 2019 used a biomarker to...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy Oct 19

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for patients with cancer....

© 2021 CureMatch, Inc. CureMatch is a registered trademark.
FAQ | Terms of Use | Privacy Policy | HIPAA Notice

We’d like to send you a CureMatch Sample Analysis

 

Sample Analysis Download Form

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data